📊 ASMB Key Takeaways
Is Assembly Biosciences, Inc.. (ASMB) a Good Investment?
Assembly Biosciences demonstrates strong revenue growth (+153.5% YoY) but is burning significant cash with negative operating income, negative free cash flow of -$41.2M, and deteriorating profitability metrics. Despite a solid balance sheet with $58.5M in cash and low debt, the company's current cash burn rate is unsustainable and threatens long-term viability without achieving profitability or securing additional funding.
Assembly Biosciences shows a materially improved top line, with revenue up 153.5% year over year, while maintaining a strong balance sheet with no meaningful leverage and ample near-term liquidity. However, the business remains unprofitable, free cash flow is deeply negative, and the quality and durability of revenue growth appear less proven than the headline growth rate suggests. Fundamentally, this looks like a well-financed but still cash-burning development-stage biotech rather than a consistently self-sustaining operating business.
Why Buy Assembly Biosciences, Inc.. Stock? ASMB Key Strengths
- Exceptional revenue growth of 153.5% year-over-year indicates strong commercial traction or successful product launches
- Strong balance sheet with $58.5M in cash, $206.8M stockholders' equity, and minimal debt (0.00x debt-to-equity ratio)
- High liquidity with current ratio of 5.22x provides runway to weather operational challenges
- Very strong liquidity with a 5.22x current ratio and $58.45M in cash
- Debt-free capital structure reduces financial risk and preserves flexibility
- Revenue growth was exceptionally strong year over year, indicating meaningful business progress
ASMB Stock Risks: Assembly Biosciences, Inc.. Investment Risks
- Severe cash burn of -$41.1M in operating cash flow with negative free cash flow margin of -56.9%, indicating revenue growth is not translating to profitability
- Operating margin of -16.8% and net margin of -8.5% show the company is not yet profitable despite substantial revenue, suggesting unsustainable cost structure
- Continued negative operating cash flow at current burn rate would exhaust cash reserves within approximately 1.4 years without achieving profitability or securing additional capital
- The company remains unprofitable with negative operating and net margins
- Operating cash flow and free cash flow are significantly negative, implying continued cash burn
- Revenue durability may be weak if growth is driven by milestone or collaboration payments rather than recurring commercial sales
Key Metrics to Watch
- Path to operating profitability and operating margin expansion
- Operating cash flow trend and time to cash flow breakeven
- Cash burn rate and runway remaining at current burn levels
- Gross margin sustainability as revenue scales
- Quarterly operating cash burn relative to cash balance
- Revenue mix and repeatability, especially whether growth converts into sustained operating margin improvement
Assembly Biosciences, Inc.. (ASMB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.22x current ratio provides a solid financial cushion.
ASMB Profit Margin, ROE & Profitability Analysis
ASMB vs Healthcare Sector: How Assembly Biosciences, Inc.. Compares
How Assembly Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Assembly Biosciences, Inc.. Stock Overvalued? ASMB Valuation Analysis 2026
Based on fundamental analysis, Assembly Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Assembly Biosciences, Inc.. Balance Sheet: ASMB Debt, Cash & Liquidity
ASMB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Assembly Biosciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.69 indicates the company is currently unprofitable.
ASMB Revenue Growth, EPS Growth & YoY Performance
ASMB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.8M | -$9.2M | $-0.72 |
| Q2 2025 | $8.5M | -$10.2M | $-1.33 |
| Q1 2025 | $5.8M | -$8.8M | $-1.17 |
| Q3 2024 | N/A | -$9.6M | $-1.51 |
| Q2 2024 | N/A | -$11.2M | $-1.98 |
| Q1 2024 | N/A | -$9.1M | $-1.66 |
| Q3 2022 | $6.3M | -$18.8M | $-0.41 |
| Q3 2021 | $6.3M | -$3.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Assembly Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
ASMB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Assembly Biosciences, Inc.. (CIK: 0001426800)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASMB
What is the AI rating for ASMB?
Assembly Biosciences, Inc.. (ASMB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASMB's key strengths?
Claude: Exceptional revenue growth of 153.5% year-over-year indicates strong commercial traction or successful product launches. Strong balance sheet with $58.5M in cash, $206.8M stockholders' equity, and minimal debt (0.00x debt-to-equity ratio). ChatGPT: Very strong liquidity with a 5.22x current ratio and $58.45M in cash. Debt-free capital structure reduces financial risk and preserves flexibility.
What are the risks of investing in ASMB?
Claude: Severe cash burn of -$41.1M in operating cash flow with negative free cash flow margin of -56.9%, indicating revenue growth is not translating to profitability. Operating margin of -16.8% and net margin of -8.5% show the company is not yet profitable despite substantial revenue, suggesting unsustainable cost structure. ChatGPT: The company remains unprofitable with negative operating and net margins. Operating cash flow and free cash flow are significantly negative, implying continued cash burn.
What is ASMB's revenue and growth?
Assembly Biosciences, Inc.. reported revenue of $72.3M.
Does ASMB pay dividends?
Assembly Biosciences, Inc.. does not currently pay dividends.
Where can I find ASMB SEC filings?
Official SEC filings for Assembly Biosciences, Inc.. (CIK: 0001426800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASMB's EPS?
Assembly Biosciences, Inc.. has a diluted EPS of $-0.55.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ASMB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Assembly Biosciences, Inc.. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ASMB stock overvalued or undervalued?
Valuation metrics for ASMB: ROE of -3.0% (sector avg: 15%), net margin of -8.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ASMB stock in 2026?
Our dual AI analysis gives Assembly Biosciences, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASMB's free cash flow?
Assembly Biosciences, Inc..'s operating cash flow is $-41.1M, with capital expenditures of $66.0K. FCF margin is -56.9%.
How does ASMB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.5% (avg: 12%), ROE -3.0% (avg: 15%), current ratio 5.22 (avg: 2).